Biocompatible and biodegradable zeolitic imidazolate framework/polydopamine nanocarriers for dual stimulus triggered tumor thermo-chemotherapy
Biocompatible and biodegradable zeolitic imidazolate framework/polydopamine nanocarriers for dual stimulus triggered tumor thermo-chemotherapy
复制标题
用于双刺激触发肿瘤热化疗的生物相容性和可生物降解的沸石咪唑酯框架/聚多巴胺纳米载体
DOI：
10.1016/j.biomaterials.2018.02.022
复制
发表时间：
2018-04-01
期刊：
影响因子：
14
通讯作者：
Meng, Xianwei
中科院分区：
文献类型：
--
作者：
Wu, Qiong;Niu, Meng;Meng, Xianwei
沸石咪唑盐框架（ZIFs）因其高载药量和固有的生物降解性而成为ph敏感的药物载体。在这项工作中，基于ZIFs （PDA-PCM@ZIF-8/DOX）合成了一种生物相容性近红外和ph响应的药物递送纳米平台，用于体内癌症治疗。经聚多巴胺修饰后，ZIFs的生物相容性得到了极大的改善，并得到了细胞毒性和体内急性毒性评价的证实。可降解性也以适当的速率进行调节。ZIFs反应条件温和，可在一锅内完成合成和载药，载药量高（37.86%），包封率高（78.76%）。同时，PDA作为光热转移剂，触发相变材料的热响应开关，实现近红外控释药物。在近红外和酸性环境的双重刺激下，药物释放率高达78%，而无刺激时仅释放21%，显示出显著的控释效果。体内抗肿瘤实验表明光热化疗组肿瘤抑制率高，具有显著的协同作用。基于ZIFs的生物相容性和可生物降解的给药平台在未来的临床癌症治疗中显示出巨大的前景。(C) 2018 Elsevier Ltd.版权所有。
Zeolitic imidazolate frameworks (ZIFs) have attracted great interest as pH-sensitive drug carrier because of high drug loading and intrinsic biodegradability. In this work, a biocompatible NIR and pH-responsive drug delivery nanoplatform based on ZIFs (PDA-PCM@ZIF-8/DOX) is synthesized for in vivo cancer therapy. The biocompatibility of ZIFs is greatly improved by polydopamine (PDA) modifying and proved by cytotoxicity and in vivo acute toxicity evaluation. The degradability is also regulated in an appropriate rate. Due to mild reaction condition of ZIFs, the synthesis and drug loading is achieved in one pot with high loading (37.86%) and encapsulation rate (78.76%). Meanwhile, PDA acts as a photothermal transfer agent to trigger thermal response switch of phase change materials for NIR controlled drug release. Under the dual stimulus of NIR and acid environment, the drug release is as high as 78%, while only 21% is released without stimulus, showing a remarkable effect of control release. In vivo anti-tumor experiments demonstrate the high tumor inhibition rate of photothermal-chemotherapy group with a significant synergistic effect. The biocompatible and biodegradable drug delivery platform based on ZIFs has shown great promise for future clinic cancer therapy. (C) 2018 Elsevier Ltd. All rights reserved.